


1/33




1-(Propoxymethyl)-maleimide

MIRA-1

Fig. 1A

BEST AVAILABLE COPY

2/33



2,2-bis(hydroxymethyl)-1-azabicyclo[2.2.2]octan-3-one

PRIMA-1

Fig. 1B

3/33

MIRA-1




Fig. 2A

TITLE: USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING  
A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES

4/33

PRIMA-1




Fig. 2A

5/33




Fig. 2B

TITLE: USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING  
A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES

6/33




Fig. 2B

7/33




Fig. 2C

8/33

Saos-2-His-273




Fig. 2C

9/33




Fig. 2D

10/33




Fig. 2D

11/33




Fig. 3A

10/505407

DOCKET NO.: 1505-1052  
INVENTOR: VLADIMIR BYKOV ET AL.  
FILING DATE: AUGUST 23, 2004

TITLE: USE OF LOW MOLECULAR WEIGHT COMPOUNDS FOR PREPARING  
A MEDICAMENT USEFUL IN TREATING MUTANT P53 MEDIATED DISEASES

12/33




Fig. 3B

13/33




Fig. 3C

14/33




Fig. 3C

15/33




Fig. 4A

16/33




Fig. 4A

17/33





Fig. 4A

18/33

GST-wtp53

PAb 240



after heating at 37°C for 30 min

% of PAb 240 epitope remaining

Fig. 4B


19/33

GST-mtp53-175

PAb 240

after heating at 37°C for 30 min


% of PAb 240 epitope remaining



means  $\pm$  SE

Fig. 4B


20/33



21/33

GST-mtp53-248

DO-1



after heating at 37°C for 30 min

% of PAb DOI epitope remaining

Fig. 4C

22/33




Fig. 5

23/33




Fig. 6A

24/33




Fig. 6B

25/33





Fig. 7

26/33



treatment with PRIMA-1

Fig. 8

10/505407

27/33




Fig. 9A

28/33






Fig. 9B

29/33




EGFP  
Hoechst  
C


Fig. 9C

30/33

A



B



C




Fig.10

31/33




Fig. 11

32/33

MIRRA-1




Fig. 12A

33/33

# PRIMA-1




Fig. 12B

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**